Novo Nordisk (NVO) Free Cash Flow (2014 - 2025)
Novo Nordisk (NVO) free cash flow from Dec 31, 2014 to Dec 31, 2025. The TTM Novo Nordisk (NVO) free cash flow is $4.45B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Free Cash Flow
Quarterly Free Cash Flow
Novo Nordisk (NVO) Free Cash Flow CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -56.46% |
| 3 Years TTM | -21.00% |
| 5 Years TTM | -6.57% |
| 10 Years TTM | -0.58% |
| All Time TTM | -0.58% |
Annual Free Cash Flow change of Novo Nordisk (NVO)
| Year | Free Cash Flow | Change |
|---|---|---|
| 2025 | $4.56B | -52.88% |
| 2024 | $9.67B | -6.70% |
| 2023 | $10B | +12.32% |
| 2022 | $9.23B | +26.74% |
| 2021 | $7.28B | +48.48% |
| 2020 | $4.91B | -8.11% |
| 2019 | $5.34B | +7.94% |
| 2018 | $4.95B | -5.63% |
| 2017 | $5.24B | -7.56% |
| 2016 | $5.67B | +22.18% |
| 2015 | $4.64B | +4.30% |
| 2014 | $4.45B | N/A |
Comparison Novo Nordisk (NVO) five years free cash flow CAGR with competitors
Novo Nordisk (NVO) five years free cash flow CAGR is -6.57%.
| Ticker | Name | five years Free Cash Flow CAGR | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | 21.25% | -423.63% |
| AZN | Astrazeneca plc | 15.68% | -338.78% |
| SNY | Sanofi | 8.08% | -223.11% |
| MRK | Merck & Co Inc | 5.49% | -183.61% |
| GILD | Gilead Sciences Inc | 3.30% | -150.22% |
| ABBV | Abbvie Inc | 2.35% | -135.79% |